Home・Aktien・Royalty Pharma PLC (Class A)

Royalty Pharma PLC (Class A)

Geschlossen

BrancheGesundheitswesen

56.62 -0.82

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

56.56

Max

57.03

Schlüsselkennzahlen
By Trading Economics
Einkommen	-61M 295M
Verkäufe	8.6M 631M
KGV Branchendurchschnitt	30.09 68.51
EPS	1.3
Dividendenrendite	1.53
Gewinnspanne	46.733
Angestellte	100
EBITDA	112M 563M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+17.14% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	1.53% 2.29%
Nächstes Ergebnis	4. Nov. 2026
Nächste Dividendenausschüttung	10. Sept. 2026
Nächstes Ex-Dividendendatum	14. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.2B 33B
Vorheriger Eröffnungskurs	57.44
Vorheriger Schlusskurs	56.62

Nachrichtenstimmung

By Acuity

81%

19%

316 / 340 Ranking in Healthcare

Royalty Pharma PLC (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Aug. 2026, 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

6. Aug. 2026, 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

5. Aug. 2026, 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

4. Aug. 2026, 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

3. Aug. 2026, 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

1. Aug. 2026, 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

31. Juli 2026, 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

30. Juli 2026, 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

29. Juli 2026, 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

28. Juli 2026, 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

27. Juli 2026, 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

24. Juli 2026, 22:21 UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

22. Juli 2026, 19:11 UTC

News

Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21. Juli 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20. Juli 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Peer-Vergleich

Kursveränderung

Royalty Pharma PLC (Class A) Prognose

Kursziel

By TipRanks

17.14% Vorteil

12-Monats-Prognose

Durchschnitt 66.5 USD 17.14%

Hoch 70 USD

Tief 65 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Royalty Pharma PLC (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Royalty Pharma PLC (Class A) – Dist abgegeben haben.

Stimmung

By Acuity

316 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.